Biosino Bio-Technology & Science Inc.
Hong Kong Stock ExchangeTotal Valuation
Biosino Bio-Technology & Science Inc. carries a market capitalization of 185.14M, placing it among publicly traded companies globally. Its enterprise value stands at 214.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 185.14M |
| Enterprise Value | 214.29M |
Share Statistics
Biosino Bio-Technology & Science Inc. currently has 144.71M shares outstanding.
| Shares Outstanding | 144.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Biosino Bio-Technology & Science Inc. trades at a trailing price-to-earnings ratio of 82.56. The price-to-sales ratio is 0.36, and the price-to-book ratio stands at 4.96.
| PE Ratio | 82.56 |
| PS Ratio | 0.36 |
| PB Ratio | 4.96 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Biosino Bio-Technology & Science Inc. trades at an EV/EBITDA multiple of 97.15 and an EV/FCF ratio of 30.66. The EV/Sales ratio of 0.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 97.15 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.74 |
| EV / EBITDA | 97.15 |
| EV / EBIT | 97.15 |
| EV / FCF | 30.66 |
Financial Position
Biosino Bio-Technology & Science Inc. maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.45, indicating elevated leverage, while an interest coverage ratio of -2.81 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.09 |
| Quick Ratio | 0.20 |
| Debt / Equity | 65.45 |
| Debt / EBITDA | -8.42 |
| Interest Coverage | -2.81 |
Financial Efficiency
| Return on Equity (ROE) | -41.91 |
| Return on Assets (ROA) | -2.00 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.79 |
Taxes
| Income Tax | 1.63M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Biosino Bio-Technology & Science Inc.'s stock has gained approximately 396.55172% over the past 52 weeks. The 50-day moving average sits at 3.20, while the 200-day moving average is 2.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | 396.55172% |
| 50-Day Moving Average | 3.20 |
| 200-Day Moving Average | 2.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Biosino Bio-Technology & Science Inc. generated 289.07M in revenue and converted that into -11.65M in net income, yielding earnings per share of -0.13. EBITDA reached -17.99M, while operating income came in at -17.99M.
| Revenue | 289.07M |
| Gross Profit | 127.37M |
| Operating Income | -17.99M |
| Pretax Income | -17.61M |
| Net Income | -11.65M |
| EBITDA | -17.99M |
| EBIT | -17.99M |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
Biosino Bio-Technology & Science Inc. holds 63.41M in cash and equivalents against 151.45M in total debt, resulting in a net debt position of 79.31M. Total book value stands at 21.23M, with working capital of 29.39M providing operational flexibility.
| Cash & Cash Equivalents | 63.41M |
| Total Debt | 151.45M |
| Net Debt | 79.31M |
| Equity (Book Value) | 21.23M |
| Book Value Per Share | 0.15 |
| Working Capital | 29.39M |
Margins
Biosino Bio-Technology & Science Inc. operates with a gross margin of 44.06, reflecting its pricing power and cost economics. The operating margin of -6.22 and net profit margin of -4.03 provide insight into operational efficiency.
| Gross Margin | 44.06 |
| Operating Margin | -6.22 |
| Pretax Margin | -6.09 |
| Profit Margin | -4.03 |
| EBITDA Margin | -6.22 |
Scores
Biosino Bio-Technology & Science Inc. posts an Altman Z-Score of 0.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.36 |